His and Her Health

In the early 1900s, the outlook was grim in general for a patient with prostate cancer, much less one who had failed conventional treatment. But today, alternative therapy is available to patients who have failed traditional treatments: hormone therapy. Now, thanks to all of these new treatments, sufferers can bask in the hope, if not the reality, of a cure.

Urology has a number of white knights that have led crusades against many debilitating urologic disorders. But perhaps none is more heroic than those innovative surgeons who have led the way in treating prostate cancer. Without the pioneering spirit of a Theodor Billroth or a Hugh Hampton Young, who adapted their prostatectomies for malignancies, men with early tumors could not choose surgery as a treatment. Without the curiosity of a Patrick C. Walsh, who investigated the gland's anatomy and crafted nerve-sparing surgical techniques, they might still face the devastating side effects of previous operations.

Silence may be golden, but not if it keeps you from getting help for urinary incontinence. For of all the urologic conditions, those concerning leaking urine are often the most neglected, especially by women who make up 85 percent of incontinence sufferers.

The race to cure cancer has been a marathon physicians and researchers have been running for decades. But, since the advent of chemotherapeutic treatments, more hurdles are being cleared than ever before. For without surgery and effective, though toxic, drugs to stop cancers in their tracks, many cancer victims might not be the survivors they are today.

PREVALENCE AND CORRELATES OF ERECTILE DYSFUNCTION IN A UNITED STATES NATIONWIDE POPULATION-BASED SAMPLE: PHASE I RESULTS

UROLOGY SALVAGE OF SILDENAFIL FAILURES FROM PRIMARY CARE PHYSICIANS

VARDENAFIL IMPROVES ERECTILE FUNCTION REGARDLESS OF ETIOLOGY OR BASELINE SEVERITY IN MEN WITH ERECTILE DYSFUNCTION

ORLANDO - May 25, 2002 -Vardenafil significantly improved erectile function (EF) in men suffering from erectile dysfunction (ED), regardless of the origin or baseline severity of their condition, according to a new study conducted by Craig Donatucci, M.D., urologist in practice at the Duke University Medical Center in Durham, NC. His findings will be presented at the American Urological Association Annual Scientific Meeting on May 27 at 2:20 p.m. during a podium session.

STUDY SHOWS NEW INVESTIGATIONAL DRUG TADALAFIL SUCCESFULLY TREATED ERECTILE DYSFUNCTION UP TO 36 HOURS AFTER DOSING

ORLANDO - May 25, 2002 - Erectile dysfunction is a strong indicator of future forms of ischemic heart disease, according to a study conducted by Dr. Francesco Montorsi at the University Vita - Salute, Scientific Institute H. San Raffaele in Milan. He will present his findings at the American Urological Association's Annual Scientific Meeting during a poster session on May 27, 2002, starting at 10:00 a.m.